Company Legal Name
Latest Valuation
Founded Year
Headquarters
insitro, Inc. develops advanced drug discovery platforms that leverage machine learning and artificial intelligence to analyze large-scale biological and clinical datasets. Founded in 2018 and headquartered in South San Francisco, the company combines computational biology with experimental validation to identify novel therapeutic targets and optimize drug development processes. By integrating multi-omics data with predictive modeling, insitro aims to reduce the time and cost traditionally associated with pharmaceutical research and development. The company focuses on transforming how drugs are discovered and developed, positioning itself at the intersection of biotechnology and artificial intelligence to accelerate the delivery of life-changing medicines to patients.
Availability of information and platform features may vary by region and applicable requirements.
Eligibility and access may depend on user location, verification status, and applicable legal or regulatory requirements.
Additional platform details may be available after account creation, where applicable.
Identity, compliance, and other review steps may be required before access to certain materials or features.
Platform details, if applicable, should be reviewed in account materials before making any decision.
Any economic terms, if applicable, should be reviewed carefully in the relevant materials.
Private market interests may be illiquid, restricted, or difficult to transfer. Users should not assume that any secondary market will be available.
Valuations may reflect past financing rounds or other available information and may not represent a price at which any person can transact.
Company and sector risks may vary by business model, technology development, competition, regulation, and market conditions.
Operational, documentation, custody, or verification processes may involve limitations, delays, or dependencies.
Regulatory, tax, and legal requirements may change and may affect information availability, platform features, or user eligibility.
